Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;20(40):3539-3547.
doi: 10.1080/14796694.2024.2355078. Epub 2024 Jun 5.

How to find a needle in a haystack: a systematic review on targeting KRAS wild-type pancreatic cancer

Antoine Mouawad  1 , Sofia Habib  1 , Marc Boutros  1 , Fouad Attieh  1 , Hampig Raphaël Kourie  2
Affiliations

How to find a needle in a haystack: a systematic review on targeting KRAS wild-type pancreatic cancer

Antoine Mouawad et al. Future Oncol. 2024 Dec.

Abstract

Aim: Pancreatic adenocarcinoma is a very aggressive type of cancer, in which targeted therapies have not yet been fully utilized. KRAS wild-type pancreatic adenocarcinoma tumors are associated with different genomic alterations in comparison to KRAS mutated pancreatic adenocarcinoma. Objective: This systematic review aims to provide a one-stop summary of all these alterations, their proposed targeted treatment and their effect on disease progression. Methods: An electronic search strategy was elaborated in the PubMed database between 2020 and January 2024. Results: 21 studies were included, and we found that the most frequent targetable genomic alterations in KRAS wild-type pancreatic adenocarcinoma were BRAF, EGFR, FGFR, MSI-H/dMMR, Her2/ERBB2 amplification, BRCA1/2 and other HRDs, and gene fusions like ALK, NTRK and NRG1.

Keywords: KRAS wild-type; Pancreatic adenocarcinoma; genomic alterations; targeted therapy; therapeutic targets.

Plain language summary

[Box: see text].

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Figures

Figure 1.
Figure 1.
PRISMA flow diagram.
Figure 2.
Figure 2.
Key targetable genomic alterations in KRAS wild-type pancreatic ductal adenocarcinoma. *In testing/awaiting results. **In other solid tumors.
See this image and copyright information in PMC

References

    1. Partyka O, Pajewska M, Kwaśniewska D, et al. . Overview of pancreatic cancer epidemiology in Europe and recommendations for screening in high-risk populations. Cancers (Basel). 2023;15(14):3634. doi:10.3390/cancers15143634 - DOI - PMC - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, et al. . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492 - DOI - PubMed
    1. Conroy T, Desseigne F, Ychou M, et al. . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825. doi:10.1056/NEJMoa1011923 - DOI - PubMed
    1. Von Hoff DD, Ervin T, Arena FP, et al. . Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703. doi:10.1056/NEJMoa1304369 - DOI - PMC - PubMed
    1. Ashok Kumar P, Serinelli S, Zaccarini DJ, et al. . Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma. Front Oncol. 2023;13:1169586. doi:10.3389/fonc.2023.1169586 - DOI - PMC - PubMed

    2. • This study was of high interest for our paper since it gave us a clear understanding of how KRAS wild-type pancreatic ductal adenocarcinoma (PDA) tumors can be stratfied according to other genomic alterations.

Publication types

MeSH terms

Substances